PHILADELPHIA, Aug. 31, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Stifel Nicolaus Healthcare Conference 2011.
Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Thursday, September 8th at 3:15PM ET. The Company’s presentation will be delivered at The Four Seasons Hotel in Boston, Massachusetts.
At the time of the presentation, a live audio and slides webcast of Echo Therapeutics’ presentation will be available at http://www.veracast.com/webcasts/stifel/healthcare2011/81212466.cfm. Echo Therapeutics recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived at the same web link for 30 days following the event.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Christine Olimpio
Director, Corporate Communications
(215) 717-4104
SOURCE Echo Therapeutics
